Skip to main content
Top
Published in: Annals of Intensive Care 1/2019

Open Access 01-12-2019 | Septicemia | Research

Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study

Authors: Felix Carl Fabian Schmitt, Vasil Manolov, Jakob Morgenstern, Thomas Fleming, Stefan Heitmeier, Florian Uhle, Mohammed Al-Saeedi, Thilo Hackert, Thomas Bruckner, Herbert Schöchl, Markus Alexander Weigand, Stefan Hofer, Thorsten Brenner

Published in: Annals of Intensive Care | Issue 1/2019

Login to get access

Abstract

Background

Septic coagulopathy represents a very dynamic disease entity, tilting from initial hypercoagulability towards a subsequent hypocoagulable disease state, entitled overt disseminated intravascular coagulation. Acute fibrinolysis shutdown has recently been described to be a crucial component of initial hypercoagulability in critically ill patients, although the underlying pathomechanisms, the specific temporal kinetics and its outcome relevance in patients with sepsis remain to be determined.

Methods

In total, 90 patients (30 with septic shock, 30 surgical controls and 30 healthy volunteers) were enrolled. Blood samples were collected at sepsis onset or prior and immediately after the surgical procedure as well as 3 h, 6 h, 12 h, 24 h, 48 h and 7 d later, whereas blood samples from healthy volunteers were collected once. Besides viscoelastic and aggregometric point-of-care testing (POCT), enzyme-linked immunosorbent and thrombin generation assays and liquid chromatography–mass spectrometry-based measurements were performed.

Results

As assessed by viscoelastic POCT, fibrinolysis shutdown occurred early in sepsis. Significant increases in tissue plasminogen activator had no effect on thromboelastometrical lysis indices (LIs). Contrariwise, plasminogen activator inhibitor-1 was already significantly increased at sepsis onset, which was paralleled by significantly increased LIs in patients suffering from septic shock in comparison with both control groups. This effect persisted throughout the 7-day observation period and was most pronounced in severely ill as well as non-surviving septic patients. Thromboelastometrical LI, therefore, proved to be suitable for early diagnosis [e.g. LI 45 min: area under the curve (AUC) up to 0.933] as well as prognosis (e.g. LI 60 min: AUC up to 1.000) of septic shock.

Conclusions

Early inhibition of plasminogen activation leads to acute fibrinolysis shutdown with improved clot stability and is associated with increased morbidity and mortality in septic patients.
Trial registration This study was approved by the local ethics committee (Ethics Committee of the Medical Faculty of Heidelberg; Trial-Code No. S247-2014/German Clinical Trials Register (DRKS)-ID: DRKS00008090; retrospectively registered: 07.05.2015). All study patients or their legal representatives signed written informed consent.
Appendix
Available only for authorised users
Literature
1.
go back to reference Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis. 2003;16(1–2):43–7.PubMedCrossRef Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis. 2003;16(1–2):43–7.PubMedCrossRef
2.
go back to reference Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128(4):2864–75.PubMedCrossRef Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128(4):2864–75.PubMedCrossRef
3.
4.
go back to reference Saito S, et al. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care. 2018;50:23–30.PubMedCrossRef Saito S, et al. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J Crit Care. 2018;50:23–30.PubMedCrossRef
5.
go back to reference Brenner T, et al. Viscoelastic and aggregometric point-of-care testing in patients with septic shock–cross-links between inflammation and haemostasis. Acta Anaesthesiol Scand. 2012;56(10):1277–90.PubMedCrossRef Brenner T, et al. Viscoelastic and aggregometric point-of-care testing in patients with septic shock–cross-links between inflammation and haemostasis. Acta Anaesthesiol Scand. 2012;56(10):1277–90.PubMedCrossRef
6.
go back to reference Moore HB, et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2540 severely injured patients. J Am Coll Surg. 2016;222(4):347–55.PubMedPubMedCentralCrossRef Moore HB, et al. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2540 severely injured patients. J Am Coll Surg. 2016;222(4):347–55.PubMedPubMedCentralCrossRef
7.
go back to reference Levy MM, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29(4):530–8.PubMedCrossRef Levy MM, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29(4):530–8.PubMedCrossRef
8.
go back to reference Toh CH, Hoots WK, S.S.C.o.D.I.C.o.t. ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost. 2007;5(3):604–6.PubMedCrossRef Toh CH, Hoots WK, S.S.C.o.D.I.C.o.t. ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost. 2007;5(3):604–6.PubMedCrossRef
9.
go back to reference Hemker HC, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4–15.PubMedCrossRef Hemker HC, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4–15.PubMedCrossRef
10.
go back to reference Morgenstern J, et al. Sensitive mass spectrometric assay for determination of 15-deoxy-Delta(12,14)-prostaglandin J2 and its application in human plasma samples of patients with diabetes. Anal Bioanal Chem. 2018;410(2):521–8.PubMedCrossRef Morgenstern J, et al. Sensitive mass spectrometric assay for determination of 15-deoxy-Delta(12,14)-prostaglandin J2 and its application in human plasma samples of patients with diabetes. Anal Bioanal Chem. 2018;410(2):521–8.PubMedCrossRef
13.
go back to reference Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost. 2007;5(Suppl 1):24–31.PubMedCrossRef Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost. 2007;5(Suppl 1):24–31.PubMedCrossRef
14.
go back to reference Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7(1):23–38.PubMedCrossRef Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7(1):23–38.PubMedCrossRef
15.
go back to reference Iyer JK, et al. Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect Immun. 2010;78(6):2418–28.PubMedPubMedCentralCrossRef Iyer JK, et al. Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect Immun. 2010;78(6):2418–28.PubMedPubMedCentralCrossRef
16.
go back to reference Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125(Suppl 1):S70–3.PubMedCrossRef Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125(Suppl 1):S70–3.PubMedCrossRef
17.
go back to reference Levi M, et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Investig. 1997;27(1):3–9.CrossRef Levi M, et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Investig. 1997;27(1):3–9.CrossRef
18.
go back to reference Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40(9):2704–8.PubMedCrossRef Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40(9):2704–8.PubMedCrossRef
19.
go back to reference Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res. 2013;131(5):383–9.PubMedCrossRef Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res. 2013;131(5):383–9.PubMedCrossRef
20.
go back to reference Warren BL, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–78.PubMedCrossRef Warren BL, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869–78.PubMedCrossRef
21.
go back to reference Ranieri VM, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64.PubMedCrossRef Ranieri VM, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64.PubMedCrossRef
22.
go back to reference Bernard GR, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709.PubMedCrossRef Bernard GR, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699–709.PubMedCrossRef
23.
go back to reference Abraham E, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–47.PubMedCrossRef Abraham E, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238–47.PubMedCrossRef
24.
go back to reference Kienast J, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4(1):90–7.PubMedCrossRef Kienast J, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4(1):90–7.PubMedCrossRef
25.
go back to reference Wiedermann CJ, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34(2):285–92.PubMedCrossRef Wiedermann CJ, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34(2):285–92.PubMedCrossRef
26.
27.
go back to reference Yoshimura J, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care. 2015;19:78.PubMedPubMedCentralCrossRef Yoshimura J, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care. 2015;19:78.PubMedPubMedCentralCrossRef
28.
go back to reference Zarychanski R, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43(3):511–8.PubMedCrossRef Zarychanski R, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43(3):511–8.PubMedCrossRef
29.
go back to reference Zarychanski R, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008;36(11):2973–9.PubMedCrossRef Zarychanski R, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008;36(11):2973–9.PubMedCrossRef
30.
go back to reference Umemura Y, et al. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016;14(3):518–30.PubMedCrossRef Umemura Y, et al. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016;14(3):518–30.PubMedCrossRef
31.
go back to reference Roberts I, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1–79.PubMedPubMedCentralCrossRef Roberts I, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1–79.PubMedPubMedCentralCrossRef
32.
33.
go back to reference Schochl H, et al. Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med. 2011;17(3–4):266–72.PubMed Schochl H, et al. Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med. 2011;17(3–4):266–72.PubMed
34.
go back to reference Boisrame-Helms J, et al. Endothelial dysfunction in sepsis. Curr Vasc Pharmacol. 2013;11(2):150–60.PubMed Boisrame-Helms J, et al. Endothelial dysfunction in sepsis. Curr Vasc Pharmacol. 2013;11(2):150–60.PubMed
35.
go back to reference Markiewski MM, et al. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184–92.PubMedCrossRef Markiewski MM, et al. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184–92.PubMedCrossRef
36.
37.
go back to reference Adamzik M, et al. Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit Care. 2010;14(5):R178.PubMedPubMedCentralCrossRef Adamzik M, et al. Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit Care. 2010;14(5):R178.PubMedPubMedCentralCrossRef
38.
go back to reference Ostrowski SR, et al. Consecutive thrombelastography clot strength profiles in patients with severe sepsis and their association with 28-day mortality: a prospective study. J Crit Care. 2013;28(3):317e1–11.CrossRef Ostrowski SR, et al. Consecutive thrombelastography clot strength profiles in patients with severe sepsis and their association with 28-day mortality: a prospective study. J Crit Care. 2013;28(3):317e1–11.CrossRef
39.
40.
41.
go back to reference Levi M, Lowenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2008;34(5):417–24.PubMedCrossRef Levi M, Lowenberg EC. Thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2008;34(5):417–24.PubMedCrossRef
42.
go back to reference Sivula M, et al. Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2009;20(6):419–26.PubMedCrossRef Sivula M, et al. Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2009;20(6):419–26.PubMedCrossRef
43.
go back to reference Cowan DH, et al. Platelet aggregation as a sign of septicemia in thermal injury. A prospective study. JAMA. 1976;235(12):1230–4.PubMedCrossRef Cowan DH, et al. Platelet aggregation as a sign of septicemia in thermal injury. A prospective study. JAMA. 1976;235(12):1230–4.PubMedCrossRef
44.
go back to reference Sheu JR, et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. Thromb Haemost. 2000;83(5):777–84.PubMedCrossRef Sheu JR, et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. Thromb Haemost. 2000;83(5):777–84.PubMedCrossRef
45.
46.
go back to reference Moncada S, Vane JR. Interrelationships between prostacyclin and thromboxane A2. Ciba Found Symp. 1980;78:165–83.PubMed Moncada S, Vane JR. Interrelationships between prostacyclin and thromboxane A2. Ciba Found Symp. 1980;78:165–83.PubMed
47.
go back to reference Ball HA, et al. Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. Intensive Care Med. 1986;12(3):116–26.PubMedCrossRef Ball HA, et al. Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. Intensive Care Med. 1986;12(3):116–26.PubMedCrossRef
48.
go back to reference Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978;30(3):293–331.PubMed Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978;30(3):293–331.PubMed
49.
go back to reference Rie M, et al. Plasma prostacyclin increases during acute human sepsis. Circ Shock. 1883;10:232. Rie M, et al. Plasma prostacyclin increases during acute human sepsis. Circ Shock. 1883;10:232.
50.
go back to reference Fink MP, et al. Plasma levels of 6-keto PGF1 alpha but not TxB2 increase in rats with peritonitis due to cecal ligation. Circ Shock. 1985;16(3):297–305.PubMed Fink MP, et al. Plasma levels of 6-keto PGF1 alpha but not TxB2 increase in rats with peritonitis due to cecal ligation. Circ Shock. 1985;16(3):297–305.PubMed
51.
go back to reference Reines HD, et al. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet. 1982;2(8291):174–5.PubMedCrossRef Reines HD, et al. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet. 1982;2(8291):174–5.PubMedCrossRef
52.
go back to reference Yaguchi A, Pradier O, Lobo F. Platelet aggregation is impaired at the level of cyclooxygenase and thromboxane synthetase in severe sepsis. Intensive Care Med. 2001;27:166.CrossRef Yaguchi A, Pradier O, Lobo F. Platelet aggregation is impaired at the level of cyclooxygenase and thromboxane synthetase in severe sepsis. Intensive Care Med. 2001;27:166.CrossRef
Metadata
Title
Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study
Authors
Felix Carl Fabian Schmitt
Vasil Manolov
Jakob Morgenstern
Thomas Fleming
Stefan Heitmeier
Florian Uhle
Mohammed Al-Saeedi
Thilo Hackert
Thomas Bruckner
Herbert Schöchl
Markus Alexander Weigand
Stefan Hofer
Thorsten Brenner
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Intensive Care / Issue 1/2019
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-019-0499-6

Other articles of this Issue 1/2019

Annals of Intensive Care 1/2019 Go to the issue